Less than 1.5% of patients expressed this mutation (TCGA, PanCancer Atlas database: 1.49%), while in the Adenocarcinoma subtype (LUAD), mutations at K-RAS were observed in around 35% of patients (37.91% and 29.13% in MSKK 2020 and TCGA Firehose Legacy databases, respectively) (Supplementary Figure 1). The gene discussed is KRAS; the disease is adenocarcinoma.